BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...diseases company Censa Pharmaceuticals Inc., gaining CNSA-001 sepiapterin, a precursor of THB in clinical testing for phenylketonuria. Censa...
...Pharmaceuticals Inc. Tetraphase Pharmaceuticals Inc. AcelRx Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Ovid Therapeutics Inc. Innovent Biologics Inc. Eli Lilly and Co. Censa Pharmaceuticals Inc. AstraZeneca...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer; gastrointestinal; inflammation

...additional models of breast cancer and SPR inhibitors in additional models of colitis and asthma. Censa Pharmaceuticals Inc....
Items per page:
1 - 2 of 2
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...diseases company Censa Pharmaceuticals Inc., gaining CNSA-001 sepiapterin, a precursor of THB in clinical testing for phenylketonuria. Censa...
...Pharmaceuticals Inc. Tetraphase Pharmaceuticals Inc. AcelRx Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Ovid Therapeutics Inc. Innovent Biologics Inc. Eli Lilly and Co. Censa Pharmaceuticals Inc. AstraZeneca...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer; gastrointestinal; inflammation

...additional models of breast cancer and SPR inhibitors in additional models of colitis and asthma. Censa Pharmaceuticals Inc....
Items per page:
1 - 2 of 2